Eliquis has annualized sales of $8B(!)—one reason BMY is +5% today despite the less than stellar results in CHECKMATE-227: https://finance.yahoo.com/news/bristol-myers-squibb-reports-second-105900543.html My prediction from 2012 (#msg-79970210) was clearly off, but I think the general idea was informed.